MML Investors Services LLC Reduces Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

MML Investors Services LLC cut its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 13.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 36,529 shares of the company’s stock after selling 5,710 shares during the quarter. MML Investors Services LLC’s holdings in Teva Pharmaceutical Industries were worth $658,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. FMR LLC boosted its stake in Teva Pharmaceutical Industries by 49.5% in the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after purchasing an additional 20,762,226 shares during the period. Clal Insurance Enterprises Holdings Ltd increased its holdings in Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after acquiring an additional 2,204,623 shares during the period. State Street Corp increased its holdings in Teva Pharmaceutical Industries by 10.0% during the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company’s stock worth $351,402,000 after acquiring an additional 1,778,268 shares during the period. Renaissance Technologies LLC boosted its holdings in Teva Pharmaceutical Industries by 13.4% in the 2nd quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after purchasing an additional 1,031,400 shares during the period. Finally, Janus Henderson Group PLC grew its position in shares of Teva Pharmaceutical Industries by 7,945.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock valued at $86,350,000 after purchasing an additional 4,732,374 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $22.09 on Friday. Teva Pharmaceutical Industries Limited has a 1-year low of $10.34 and a 1-year high of $22.17. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The business has a 50 day moving average of $17.79 and a 200 day moving average of $17.52. The company has a market capitalization of $25.03 billion, a price-to-earnings ratio of -25.99, a PEG ratio of 0.99 and a beta of 0.79.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on TEVA shares. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.88.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.